FCGR2B and B-cell chronic lymphocytic leukemia: Although we do not know the mechanism by which these preparations impair BCR signalling on leukemic cells, we do know that CLL cells express both FcɣRIIb and CD2218, which are receptors that negatively modulate BCR-mediated activation on B cells by interacting with IgG.